Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 35Nivolumab 14Docetaxel 11atezolizumab 10Paclitaxel 9Carboplatin 7Gemcitabine 6Cisplatin 6Trastuzumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5fludarabine 4avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4cemiplimab 3Taxes 3Polymerase Chain Reaction 3Pemetrexed 3Irinotecan 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × vofatamab × Genitourinary × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡